Insider selling
Traded Jul 14, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
The CEO of Monopar Therapeutics sold $672K of Monopar Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 24, 2025 · Filed Sep 26, 2025
A major shareholder of Monopar Therapeutics sold $35M of Monopar Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$34,999,957
Shares × reported transaction price
43 days after results of Aug 12, 2025, 50 days before results of Nov 13, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $73.04 on Sep 24, 2025, at its 52-week high, after a 103% rise over the previous 30 trading days
52-week range $4.63 (Oct 23, 2024) to $73.04 (Sep 24, 2025), 100% of the way up, from 240 adjusted closes. 30 trading days earlier: $35.90 on Aug 12, 2025. Describes the past only, not a forecast
RSI 80, 97% above its 200-day average, 68% above its 50-day average, at the 52-week high, 20-day volatility 101% a year, against the S&P 500: +137 points over 1 month, +120 points over 3 months, +79 points over 6 months
From the adjusted closes up to Sep 24, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Tactic Pharma LLC's largest sale of MNPR in their filings since 2021
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +31.1% | +1.2% | +29.9% |
| 30 days | +10.9% | +3.6% | +7.3% |
| 90 days | −13.6% | +3.6% | −17.3% |
| 180 days | −29.8% | −4.8% | −25.0% |
| 365 days | +5.4% | +15.2% | −9.8% |
Past results only. Not a forecast.
Insider selling
Traded Jul 14, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
The CEO of Monopar Therapeutics sold $672K of Monopar Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Jul 14, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
A Monopar Therapeutics director sold $672K of Monopar Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Jul 14, 2025 · filed 3 days laterNot reported under a pre-arranged trading plan
A Monopar Therapeutics director sold $356K of Monopar Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.